Arbutus Biopharma (ABUS) has released an update.
Arbutus Biopharma Corporation, a clinical-stage company focused on developing treatments for chronic hepatitis B, is set to engage with investors at two major conferences in New York. They will present at the H.C. Wainwright Global Investment Conference and have a fireside chat at the Baird Global Healthcare Conference, with live webcasts available for both events.
For further insights into ABUS stock, check out TipRanks’ Stock Analysis page.
